Free Trial

Addus HomeCare (NASDAQ:ADUS) Given New $102.00 Price Target at Barclays

Addus HomeCare logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Barclays cut its price target on Addus HomeCare from $112 to $102 and kept an underweight rating, implying only about a 3.4% upside from the current share price.
  • Analyst consensus is more positive overall, with an average rating of Moderate Buy and a consensus price target of $133.22 (1 Strong Buy, 7 Buys, 2 Holds, 1 Sell).
  • Insiders have been selling recently—EVPs Darby Anderson and Michael Wattenbarger sold shares on Feb. 25—and insiders sold a total of 16,610 shares (~$1.77M) over the last 90 days, while institutional investors own about 95%+ of the stock.
  • MarketBeat previews top five stocks to own in May.

Addus HomeCare (NASDAQ:ADUS - Get Free Report) had its price target decreased by stock analysts at Barclays from $112.00 to $102.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has an "underweight" rating on the stock. Barclays's target price points to a potential upside of 3.42% from the company's current price.

ADUS has been the subject of a number of other research reports. Truist Financial set a $135.00 price objective on Addus HomeCare and gave the company a "buy" rating in a report on Wednesday, January 7th. Stephens decreased their target price on Addus HomeCare from $140.00 to $135.00 and set an "overweight" rating for the company in a research report on Wednesday, February 25th. Royal Bank Of Canada restated an "outperform" rating and issued a $139.00 price target on shares of Addus HomeCare in a report on Wednesday, February 25th. Wall Street Zen lowered shares of Addus HomeCare from a "strong-buy" rating to a "buy" rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Addus HomeCare in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $133.22.

Read Our Latest Stock Analysis on Addus HomeCare

Addus HomeCare Stock Down 0.7%

Shares of NASDAQ ADUS opened at $98.63 on Wednesday. Addus HomeCare has a 1 year low of $91.35 and a 1 year high of $124.43. The firm has a 50-day simple moving average of $106.46 and a two-hundred day simple moving average of $111.39. The company has a market cap of $1.84 billion, a P/E ratio of 19.23, a PEG ratio of 1.39 and a beta of 0.92. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.80 and a quick ratio of 1.80.

Insider Activity

In related news, EVP Darby Anderson sold 396 shares of the firm's stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $105.36, for a total transaction of $41,722.56. Following the sale, the executive vice president owned 46,246 shares of the company's stock, valued at $4,872,478.56. This trade represents a 0.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael D. Wattenbarger sold 300 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $105.36, for a total transaction of $31,608.00. Following the sale, the executive vice president directly owned 9,444 shares of the company's stock, valued at approximately $995,019.84. The trade was a 3.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 16,610 shares of company stock worth $1,768,970 over the last ninety days. 4.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ADUS. Hsbc Holdings PLC grew its stake in shares of Addus HomeCare by 57.5% during the fourth quarter. Hsbc Holdings PLC now owns 7,860 shares of the company's stock worth $847,000 after acquiring an additional 2,870 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of Addus HomeCare by 73.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 325 shares of the company's stock worth $35,000 after buying an additional 138 shares during the period. Invesco Ltd. grew its holdings in shares of Addus HomeCare by 7.1% during the fourth quarter. Invesco Ltd. now owns 416,857 shares of the company's stock valued at $44,766,000 after buying an additional 27,683 shares during the last quarter. Caitlin John LLC acquired a new stake in Addus HomeCare during the 4th quarter worth about $183,000. Finally, Empowered Funds LLC raised its stake in shares of Addus HomeCare by 186.1% in the fourth quarter. Empowered Funds LLC now owns 70,927 shares of the company's stock worth $7,617,000 after purchasing an additional 46,137 shares during the last quarter. 95.35% of the stock is owned by institutional investors and hedge funds.

Addus HomeCare Company Profile

(Get Free Report)

Addus HomeCare NASDAQ: ADUS is a leading provider of home and community-based care services for elderly, disabled, and medically complex individuals across the United States. Through a network of company-owned and franchise locations, the company delivers a broad spectrum of non-medical personal care and licensed home health services designed to support clients' independence and quality of life.

The company's core offerings include personal care assistance—covering daily living activities, medication reminders, and light housekeeping—and skilled home health services delivered under the supervision of registered nurses and licensed therapists.

Read More

Analyst Recommendations for Addus HomeCare (NASDAQ:ADUS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Addus HomeCare Right Now?

Before you consider Addus HomeCare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Addus HomeCare wasn't on the list.

While Addus HomeCare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines